A Phase 2 interventional study of IW-6463 Tablets in MELAS, sponsored by Tisento Therapeutics. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.
Sponsored by Tisento Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in MELAS Syndrome with a site in United States — 6 open to participants now, 6 under way, 1 of them phase 3. MELAS Syndrome · United States.
Among the 21 studies in MELAS Syndrome with a site in United States, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 2, and was the 13th registered.
37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.
Browse MELAS Syndrome studies →6 of the 21 studies in MELAS Syndrome with a site in United States are open now. Recruiting first, the newest first:
Khondrion BV · Sites in United States, Denmark, France and 4 more countries
Ages 18+
Michio Hirano, MD · Sites in United States
Ages 18–80
Columbia University · Sites in United States, Canada
Healthy volunteers
Columbia University · Sites in United States
Ages 4+ · Healthy volunteers
Columbia University · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 MELAS Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 3 · Phase 4 1
First in 1978; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 24 across 29 interventional studies indexed under MELAS Syndrome.
Median enrollment 27 across the 15 interventional studies, 300 across the 5 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
Tisento Therapeutics is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Tisento Therapeutics has 3 studies filed under MELAS Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in MELAS Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in MELAS Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.
IW-6463 tablets will be orally administered once-daily (QD) for up to 29 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg.
Drug: IW-6463 Tablets
IW-6463 tablets administered orally (daily)
Also known as: CY6463, zagociguat
Number of Participants With Study Drug Dose Reductions or Discontinuations Due to ≥ 1 Treatment Emergent Adverse Event (TEAE)
A TEAE is defined as an adverse event (AE) with an onset that occurs between the first dose of study drug and the end of study period. AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment.
Time frame: From first dose date to Day 43 (±4)
Number of Participants Who Experienced ≥1 AE, TEAE, Serious AE (SAE), or TEAE of Special Interest (AESI)
AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment. A TEAE is defined as an AE with an onset that occurs from the first dose of study drug up until the end of study period. An SAE is an AE that fulfills 1 or more of the following: results in death; is immediately life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event that may jeopardize the participant or may require medical intervention to prevent 1 of the outcomes listed above. Events were categorized as mild, moderate, or severe and as related or unrelated to study drug. AESIs include bleeding events, symptomatic hypotensive events and/or tachycardia, dizziness, syncope, and TEAEs related to change of neurobehaviors (ie, suicidality or euphoria).
Time frame: From first dose date to Day 43 (±4)
| Milestone | IW-6463 |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
A TEAE is defined as an adverse event (AE) with an onset that occurs between the first dose of study drug and the end of study period. AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment.
| Participants | IW-6463 |
|---|---|
| Dose reduction due to TEAE | 1 |
| Study drug discontinuation due to TEAE | 0 |
AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment. A TEAE is defined as an AE with an onset that occurs from the first dose of study drug up until the end of study period. An SAE is an AE that fulfills 1 or more of the following: results in death; is immediately life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event that may jeopardize the participant or may require medical intervention to prevent 1 of the outcomes listed above. Events were categorized as mild, moderate, or severe and as related or unrelated to study drug. AESIs include bleeding events, symptomatic hypotensive events and/or tachycardia, dizziness, syncope, and TEAEs related to change of neurobehaviors (ie, suicidality or euphoria).
| Participants | IW-6463 |
|---|---|
| Any AE | 8 |
| Any pretreatment AE | 1 |
| Any TEAE | 8 |
| Any severe TEAE | 0 |
| Any study drug-related TEAE | 4 |
| Any SAE | 0 |
| Any TEAE leading to study drug discontinuation | 0 |
| Any TEAE leading to death | 0 |
| Any treatment-emergent AESI | 4 |
Collected over From signing of informed consent (all-cause mortality) or first dose date (adverse events) to Day 43 (±4).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IW-6463 | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Event | IW-6463 |
|---|---|
| HeadacheNervous system disorders | 3/8 |
| Oedema peripheralGeneral disorders | 2/8 |
| Cerebrovascular accidentNervous system disorders | 1/8 |
| Disturbance in attentionNervous system disorders | 1/8 |
| DizzinessNervous system disorders | 1/8 |
| DysarthriaNervous system disorders | 1/8 |
| HypoaesthesiaNervous system disorders | 1/8 |
| Abdominal pain upperGastrointestinal disorders | 1/8 |
| ConstipationGastrointestinal disorders | 1/8 |
| DiarrhoeaGastrointestinal disorders | 1/8 |
| Age, Continuous(years) | IW-6463 |
|---|---|
| Mean | 32.8 ± 12.41 |
| Sex: Female, Male(Participants) | IW-6463 |
|---|---|
| Female | 5 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | IW-6463 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | IW-6463 |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Jan 2022, 14 months.
Results were first posted in Nov 2023, 1 year 9 months after primary completion. A results delay was requested in Jan 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zagociguat
Tisento Therapeutics